Based on a review of data, the panel consensus was that pembrolizumab is supported by high-level evidence (category 1) in the following settings:

- Adjuvant treatment for stage IIIA (AJCC 7th Edition) with sentinel lymph node (SLN) metastasis >1 mm (after wide local excision with or without complete lymph node dissection (CLND)). (ME-4)
- Adjuvant treatment for stage IIIB/C (AJCC 7th Edition) with sentinel node positive disease (after wide local excision with or without CLND). (ME-4)

Based on the votes above, the panel added the following language to footnote “x”: “Adjuvant dabrafenib/trametinib and pembrolizumab are category 1 options for patients with AJCC 7th Edition stage IIIA with SLN metastasis >1 mm or stage IIIB/C disease.”

Based on a review of data, the panel consensus was that pembrolizumab is supported by high-level evidence (category 1) in the following settings:

- Adjuvant treatment for newly-diagnosed Stage III (clinically positive node [s]), after wide local excision and complete therapeutic lymph node dissection (ME-5)
- Adjuvant treatment for completely resected nodal recurrence (ME-14)

Reference: